SCHEMBL266896

SCHEMBL266896

Cc1ccc(C=NNC(=O)c2cc3ccccc3cc2NC(=O)c2cccc(CN3CCN(CCO)CC3)c2)cc1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.42
POLB P06746 2/20 0.42
MAPT P10636 2/20 0.42
KMT2A Q03164 2/20 0.42
HPGD P15428 2/20 0.42
GAA P10253 1/20 0.42
HTT P42858 1/20 0.42
HPGDS O60760 1/20 0.41
DNM1 Q05193 2/20 0.40
ECE2 P0DPD6 1/20 0.40
ECE1 P42892 1/20 0.40
MUS81 Q96NY9 1/20 0.40
PKM P14618 2/20 0.39
RAB9A P51151 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
ALDH1A1 P00352 2/20 0.39
RECQL P46063 1/20 0.39
BLM P54132 1/20 0.39
CASP6 P55212 1/20 0.39
MCL1 Q07820 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL266895 1.00 MEN1 (0.42) MEN1POLBMAPTKMT2AHPGD
SCHEMBL267487 0.92 ACHE (0.43) MEN1POLBMAPTKMT2AHPGD
SCHEMBL267486 0.92 ACHE (0.43) MEN1POLBMAPTKMT2AHPGD
SCHEMBL267540 0.89 ACHE (0.52) MEN1POLBMAPTKMT2AHPGD
SCHEMBL267541 0.89 ACHE (0.52) MEN1POLBMAPTKMT2AHPGD
SCHEMBL267618 0.88 SLC34A2 (0.50) MEN1POLBMAPTKMT2AHPGD
SCHEMBL267619 0.88 SLC34A2 (0.50) MEN1POLBMAPTKMT2AHPGD
SCHEMBL268490 0.88 HPGDS (0.42) POLBMAPTHPGDSRAB9AL3MBTL1
SCHEMBL268489 0.88 HPGDS (0.42) POLBMAPTHPGDSRAB9AL3MBTL1
SCHEMBL267411 0.86 CA1 (0.40) MEN1POLBMAPTKMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 MEN1 1194/4885POLB 3843/4885MAPT 4195/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 MEN1 1638/4885POLB 3761/4885MAPT 4648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.